Biotin for Platelet Studies in Healthy Subjects

This trial examines how effectively biotin (vitamin B7) can label platelets for tracking in blood studies. Researchers add biotin and a small amount of radioactive material to platelets to track them once reintroduced into the bloodstream. Generally healthy individuals who meet specific blood donation guidelines are suitable for this trial. Participants should not have taken aspirin or similar medications recently and must agree to use birth control during the study. As a Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants the chance to be among the first to experience this innovative approach.

You may need to stop taking certain medications. Specifically, you should not take aspirin-containing medications within 7 days or platelet-inhibiting medications within 14 days before platelet collection.

Research has shown that using biotin-labeled platelets in humans is safe, particularly with small amounts of biotin. Biotin, or vitamin B7, is generally safe and non-toxic, even in large doses. However, biotin can interfere with some lab tests, potentially leading to incorrect results. Despite this, labeling platelets with biotin offers a promising method for tracking them in the body. Overall, current evidence suggests that biotin-labeled platelets are well-tolerated in humans, with measures in place to minimize any impact on lab tests.¹²³⁴⁵

Researchers are excited about biotin-labeled platelets because they offer a novel way to study platelet behavior in the body. Unlike traditional methods that rely on indirect measurements, this approach uses biotin to directly label and track platelets, providing more precise data on how platelets function. This innovative method could lead to better understanding and treatment of platelet-related conditions, as it allows scientists to observe platelet activity in real-time with greater accuracy.

This trial will study biotin-labeled platelets in healthy subjects. Studies have shown that biotin, or vitamin B7, can mark platelets, which are small blood cells that aid in clotting. One study found that 98.4% of platelets were successfully marked with biotin, meeting blood bank standards. Biotin-marked platelets enable researchers to track and study platelet lifespan and recovery post-transfusion. This method is promising because it offers insights into platelet function without altering their natural behavior. Overall, using biotin is considered an effective alternative to older methods, such as radioactive materials.¹²³⁶⁷